On December 1, 2025, the new USP chapter <382> “Elastomeric Component Functional Suitability in Parenteral Product Packaging/Delivery Systems” will take effect. It represents a fundamental shift in how primary packaging systems for parenteral drugs are evaluated:
The testing responsibility moves from the component supplier to the drug product manufacturer, shifting the focus from individual components to the overall performance of the packaging system.
New test requirements
For the first time, USP <382> requires in-use integrity testing to ensure that elastomeric components such as stoppers, plungers, or cartridge seals remain tight after multiple punctures. The former “Self-sealing capacity” test from USP <381> will be removed and replaced by the new “Needle Self-Sealing Capacity” test in USP <382>.
Because elastomeric closures are used in a variety of packaging systems – including vials, bottles, prefilled syringes, cartridges, pens, and IV bags – both initial and in-use integrity testing will be required in the future.
Testing challenges for complex systems
Testing the in-use integrity of complex packaging systems, such as prefilled syringes, presents particular challenges. Methods like laser headspace analysis or vacuum decay testing assess only overall system integrity. In contrast, the dye ingress (blue bath) method established at Labor LS allows component-specific testing, providing clear evidence of in-use integrity for individual closure systems.
Expertise from Labor LS
Labor LS offers a range of validated methods to assess the integrity of packaging systems and supports manufacturers in implementing the new USP <382> requirements. Our testing expertise ensures reliable results for regulatory compliance, quality, and patient safety.
